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CAR-T CELL THERAPY FOR LIVER METASTASES  
NELYA LASHTUR 
ABSTRACT 
 Liver metastases are the most common cause of death in colorectal cancer 
patients. The standard of care and potential for cure for colorectal liver metastases is 
resection, but often times disease it too extensive for this treatment. Over the years, 
cancer research has made way for advances in treating progressive disease through 
immunotherapy. By genetically modifying an individual’s immune system using virally 
transduced chimeric antigen receptor T cells (CAR-T), patients are better able to receive 
exquisitely specific T cells to target specific tumors. Furthermore, selective delivery 
strategies may enhance efficacy while limiting detrimental, systemic adverse effects. Not 
only this, CAR-Ts have also lead to complete remission in some liquid tumors while 
maintaining the potential for remission in solid tumors as well. This literature review 
takes readers through the emergence of the different generations of CAR-T and the 
various studies including clinical trials that have demonstrated the safety and efficacy of 
CAR-T.  
The second portion of this paper will outline the design for a phase II clinical trial 
using intrahepatic CAR-T therapy in addition to selective internal radiation therapy 
(SIRT) for refractory CEA+ colorectal liver metastases. Benefits and limitations of using 
these therapies are further discussed.    
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INTRODUCTION 
Background 
Colorectal cancer (CRC) is one of the most prevalent cancers in the United States, 
more specifically the 4th most common cancer and the second leading cause of cancer-
related deaths.1 Risk factors include advanced age, male sex, and African American 
descent. According to the National Cancer Institute, there were approximately 1,177,556 
people living with CRC in the U.S. in 2013. The overall 5-year survival rate is 65%; if 
the cancer remains localized, 5-year survival is roughly 90%. However, once metastatic 
or stage IV disease is diagnosed, likelihood of survival at 5 years plummets to a mere 
13%.1 One of the major manifestations of CRC is metastasis to the liver, which occurs 
roughly in 30% of cases at the time of presentation, and an additional 30% at some point 
during the course of their disease. Liver metastasis is a major cause of death in patients 
with primary adenocarcinoma; only 20% of patients with colorectal liver metastases 
(CLM) have resectable disease while the other 80% will most likely die despite receiving 
several lines of chemotherapy.2 
Cancer researchers have recently made several breakthroughs in developing 
alternatives to traditional therapy, which includes surgical resection, chemotherapy, 
and/or radiation therapy. These novel approaches range from cancer vaccines to adoptive 
immunotherapy using genetically modified chimeric antigen receptor T cells (CAR-T). 
CAR-T therapy has been utilized in the past few years and has shown promise in either 
stabilizing disease or mediating tumor regression in cases of lymphoma or leukemia, so 
called “liquid tumors.”3,4 The difficulty, however, has been in treating solid tumors due to 
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challenges in delivering a sufficient number of CAR-T while sparing normal organs.5 
Current research has been attempting to overcome these boundaries to make CAR-T 
therapy safe and efficient in treating solid tumors as well.  
 
Statement of the Problem 
The standard of care for CLM, which is also potentially curative, is currently 
resection in the context of multidisciplinary management.6 However, what happens when 
disease is so extensive that resection is not an option and multiple chemotherapy trials 
have failed? CAR-T immunotherapy is one of the most recent, innovative alternative 
therapies to cancer treatment. While research has shown that CAR-T therapy has been 
effective in eradicating blood-borne cancers and lymphomas, it is more difficult to assess 
how they would fare in patients with progressive CLM. This study addresses the 
following question: would CAR-T infusions plus radiation therapy be safe and effective 
in chemotherapy-resistant and progressing liver metastases originating from 
gastrointestinal adenocarcinoma?   
 
Hypothesis 
Regional hepatic infusion of CAR-T in combination with selective internal 
radiation therapy (SIRT) is safe and effective for treating advanced, unresectable 
carcinoembryogenic antigen (CEA) + liver metastases that are refractory to other 
interventions. Safety will be measured using the Common Terminology Criteria for 
Adverse Events (CTCAE) Protocol. The efficacy of this intervention combination will be 
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assessed in the form of progression-free survival (PFS) by grading tumors from imaging 
data via the modified Response Evaluation Criteria in Solid Tumors (mRECIST).  
Objectives  
 The cure for cancer has always been a relevant topic in the scientific research 
realm and an important societal goal. However, understanding that cancer is not one 
disease, but a highly heterogeneous group of conditions, make a personalized therapy 
such as CAR-T appealing. This therapy is generated in such a way to target an 
individual’s specific malignancy based upon validated bioassays. There is a current 
standard of care for CLM that has lead to prolonged disease free-survival in many 
patients or cure in those eligible for complete surgical resection.6,2 However, these 
treatments are not without adverse events. Chemotherapy uses highly toxic drugs with 
variable side effects while resection is associated with the risks related to major 
abdominal surgical procedures. If disease is too extensive, as is the case in most CLM 
patients, resection may not even be possible. The use of regional immunotherapy 
attempts to decrease the risk of systemic adverse events while also being more effective 
compared to the previous modalities. It has already shown to be safe in patients with 
CLM, for example.7 Radiation therapy also has a number of adverse events that correlate 
with higher incidence if given more frequently or over a larger surface area. This study 
further explores the safety and efficacy of using CAR-T plus a single administration of 
radiation therapy and how re-engineering of patient T cells may effectively treat liver 
metastases.       
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Specific Aims  
 To asses the safety and efficacy of using CAR-T cell liver infusions in 
combination with radiation therapy by conducting a Phase II clinical trial.  
 Assess progression-free survival in this population of patients as the primary 
outcome.   
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REVIEW OF THE LITERATURE 
Overview 
 Colorectal cancer (CRC) causes close to 500,000 deaths worldwide annually.8 
The majority of these deaths are attributed to metastatic disease to the liver, as mentioned 
above. Once CRC has transitioned to late stage metastatic disease, it is extremely difficult 
to stabilize, let alone to cure. This review of the literature will take readers through the 
current standard of treatment for CLM, the use and efficacy of immunotherapy, 
specifically CAR-T therapy in various liquid and solid tumors, immunosuppression in the 
liver and reasons why new approaches must be explored to treat liver disease, and finally, 
current research where CAR-T therapy has been used in CLM.      
 
Existing research 
Current standard of care for CLM  
 Over the past 20 years, the standard of care for CLM has been resection.6 This has 
been the only therapy that has been shown to be curative.9 However, some have criticized 
resection as the gold standard due to a lack of prospective randomized clinical trials 
assessing this data. However legitimate these concerns, it may not be completely feasible 
for surgeons to continually evaluate the benefits of resection for long periods of time and 
instead they base their reasoning to resect on retrospective data that has already been 
established. Importantly, it is undeniable that 15-20% of patients with CLM are cured 
following liver resection. In addition, when thinking of metastasis related to any 
malignancy, most would consider this a state of systemic disease. When CRC 
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metastasizes, it metastasizes to the liver 60-70% of the time6,8 and out of those patients, 
20-35% will not have evidence of any extra-hepatic involvement. Many patients with 
multifocal metastases will have liver-dominant disease rendering liver-directed therapy 
an important component of their management.  Although the disease has still 
metastasized from the distal GI tract, it is confined to the liver and thus, resection is a 
possible means of cure for CLM and the only curable therapy thus far. CAR-T may very 
well be the first step in treating CLM in order to possibly convert to resectability.  
 Tomlinson et al. performed a retrospective review looking at long-term disease-
free survival from a hepatobiliary database of patients with CLM at least 10 years post-
resection. 6 Their aims were to assess whether resection was a true cure for CLM and 
whether other characteristics of disease including tumor burden were major prognostic 
factors. The study included 644 patients from Memorial Sloan-Kettering Cancer Center 
with CLM who had their tumors resected between the years 1985-1994. This study 
design afforded robust follow-up in order to assure more accurate survival data. They 
looked at a number of variables including age, sex, disease-free interval (DFI), which was 
characterized by the time period from primary resection to recurrence, size or number of 
CLMs, the extent of resection, pre-resection carcinoembryonic antigen (CEA) levels, and 
the necessity for adjuvant hepatic-arterial infusional chemotherapy (HAIC). The clinical 
risk score (CRS) was used to predict survival. This number takes into account several 
preoperative factors including DFI < 12 months, presence of multiple hepatic metastases, 
(the largest one being > 5 cm), and CEA > 200 ng/mL. Each factor was given a value of 1 
point. A score of 5 was equivalent to a worse prognosis. This score as well as Kaplan-
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Meyer survival curves were used to assess whether resection could lead to long-term 
survival and can thus be considered a cure for CLM.6   
 Results indicated that out of all the patients assessed, 102 were found to be cancer 
survivors 10 years from the time of resection without any evidence of recurrent disease.6 
The Kaplan-Meier survival curve in Figure 1 shows a plateau beginning at 10 years 
depicting the 102 patients who had actual disease-free survival. This represents a 17-25% 
cure rate. Out of these 102 patients, 16 had recurrent disease, which was treated with 
another surgical resection; only one of those 16 patients died a cancer-related death. 
Nevertheless, researchers were able to define cure at 10 years post resection.6    
 
 
Figure 1: 10-year survival in CLM patients post resection; Kaplan-Meier plot of disease-specific survival for 612 
patients with potential 10-year follow-up who underwent resection of colorectal liver metastases from 1985 to 
1994 at Memorial Sloan-Kettering Cancer Center (adapted from Tomlinson et al; Actual 10-Year Survival After 
Resection of Colorectal Liver Metastases Defines Cure).6    
  
While resection is potentially curative, what happens when the extent of disease is so 
great that surgical resection is not an option? Data show that a mere 10-15% of people 
with CLM are actual candidates to receive resection with a 5-year survival of 35%.9,2 In 
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this situation, patients could be treated with neoadjuvant systemic or hepatic artery 
infusion (HAI) chemotherapy, or a combination of both in order to convert their disease 
to resectability. Conversion is even more likely if the extent of disease remains confined 
to the liver. It has been shown in a previous study that using a combination of 
fluorouracil, leucovorin, and oxaliplatin lead to a 15% increase in conversion to 
resecatbility for CLM. Using HAI would decrease the need for high amounts of systemic 
chemotherapy and thus decrease systemic toxic effects.2  
 A phase I clinical trial was conducted involving 49 patients with unresectable 
liver metastases from primary colorectal adenocarcinoma. 2 Characteristics of these 
patients’ disease included the following: involvement of 6 or more segments, major 
vessel involvement, and absence of disease outside the liver. Disease in both lobes and 
number of liver tumors were not factors excluding patients from resection but adequate 
liver functioning was required in order to enter trial. A CT angiogram was performed on 
all patients in order to assess blood supply and possible tumor involvement of the hepatic 
arteries. Patients then underwent pump surgery where the infusional pump catheter was 
placed in the hepatic circulation approximately 2-3 weeks before they were divided into 
two treatment cohorts; the first cohort received 4 weeks of systemic chemotherapy 
(oxaliplatin and irinotecan) while concurrently receiving HAIs of floxuridine and 
dexamethasone. The second cohort received 5 weeks of HAI therapy (floxuridine and 
dexamethasone) with escalating doses of systemic chemotherapy (oxaliplatin and 
irinotecan). Measured outcomes included tumor regression, disease progression, or 
extreme toxicity.2  
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 The major toxicities that patients experienced in both cohorts were grade 3-4 
diarrhea and neutropenia.2 Later toxicities include neurotoxicity, elevated bilirubin, 
elevated alkaline phosphatase and aspartate transaminase (AST). In regards to clinical 
activity, results showed that out of the total sample population of 49 patients, 45 patients 
(92%) had either a complete (8%) or partial response (84%). A complete response was 
characterized by absence of any disease on CT and normal CEA levels while a partial 
response was characterized by a 50% or greater reduction in tumor size. Lastly, stable 
disease, defined as a reduction in tumor size, was less than 50% in the absence of 
progression. Researchers also found that for those patients who had never received 
chemotherapy in the past, 100% of them responded to this treatment regimen. Twenty-
three of these patients were able to undergo resection, followed by administration of 
systemic chemotherapy. Interestingly enough, extent of disease in these patients did not 
correlate with a decreased probability of resection. Resectability was not related to 
number or size of metastases, clinical risk score, primary tumor location, or involvement 
of the major vessels surrounding the liver, as determined by univariate analysis. Several 
patients who had involvement of all 8 liver segments as well as total hepatic vein 
involvement were candidates for resection at the end of the trial. In fact, the only variable 
that was associated with increased conversion to resectability was female sex, with an 
81% and 30% resection rate for females and males respectively (P=.006). When 
comparing the two different cohort treatments, the resection rate for the 4-week treatment 
regimen was 36% and for the 5-week regimen, 56%.2   
 10 
     In conclusion, Kemeny et al. found that in order for extensive disease to 
become resectable, it must first be down-staged.2 In addition, certain characteristics of 
“advanced” disease such as tumor size and number do not preclude downstaging of CLM 
to resectable status. The researchers state that one of the greatest discrepancies that 
prevents other researchers from gathering accurate data that links adjuvant therapy with 
resectability is non-uniform criteria when comparing different trials. The definition of 
“unresectable disease” and delineation of the factors that would lead to resectability is not 
always the same across the board, thus making it difficult to determine whether disease is 
truly resectable, and thus might be eradicated sooner with the appropriate intervention.2  
Systemic Chemotherapy in CLM  
The first-line chemotherapy regimen that results in the best outcomes in overall 
survival for advanced CRC or unresectable CLM has been exposure to the following 
cytotoxic agents: Fluorouracil (FU) + leuvocorin (LV), Irinotecan (CPT-11), and 
Oxaliplatin (LOHP).10 This combination is also known as FOLFOXIRI. Another 
combination of Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) has also shown to be 
efficacious; this was the first-line therapy before FOLFOXIRI emerged. The Hellenic 
Oncology Research Group (HORG) ran a multicenter randomized Phase III clinical trial 
comparing FOLFOXIRI and FOLFIRI.11 However, they did not find any significant 
difference in overall survival (P=0.337), time to disease progression (P=0.17), and 
response rates (P= 0.168) between the FOLFOXIRI and FOLFIRI arms. They did find 
higher rates of alopecia, diarrhea, and neurotoxicity in the FOLFOXIRI group.11    
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Another group of oncologists (The Gruppo Oncologico Nord Ovest, GONO) 
conducted another phase III trial comparing these two chemotherapy regimens in order to 
assess PFS and overall survival (OS).12 They randomly assigned 244 patients with 
unresectable, chemotherapy-naïve CLM to the two different treatment arms. The 
FOLFOXIRI patients had developed neurotoxicities and neutropenia, but they generally 
tolerated the treatment well. This group had an increased rate of secondary resection post 
therapy, a 3-month increase in PFS, longer OS and decreased early progression to 
disease.12  
As previously mentioned, chemotherapy is often used in order to convert disease 
to resecatbility but it is also used with adjuvant intent after resection.13,14 This is because 
recurrence of disease (either hepatic or disease outside the liver) develops in 70% of 
patients who have undergone resection.8 Half of those recurrences occur in the liver 
within the first two years after resection.9 Nordlinger et al. conducted a Phase III trial 
assigning 364 patients with resectable colorectal liver metastases into two treatment arms. 
Patients in the first arm received perioperative FOLFOX-4 and resection while the second 
arm received surgery alone.15 The reasoning behind giving perioperative chemotherapy 
was to treat micrometastatic disease and to ensure administration of systemic therapy. 
Results showed an increase in PFS in the first arm (P=.058) but no overall significant 
differences in OS of the two arms. However, the patients treated with FOLFOX also 
developed higher levels of postoperative complications including hepatic failure, intra-
abdominal infection, and biliary fistula.  
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While chemotherapy may have a good response rate and may be used in various 
ways to allow either for resectability in some patients or perhaps increased overall 
survival post-resection, the cure rate of chemotherapy alone is still currently negligible. 
Recurrence may still occur even after adjuvant chemotherapy.    
Immunotherapy  
 The immune system has been studied extensively and yet researchers are always 
discovering something new about it. This has been especially true in the past several 
years; our study and knowledge about tumorigenesis and how tumors evade the immune 
system has lead to the development of new cancer therapies.16 The typical treatment for 
any type of malignancy has traditionally been surgery, chemotherapy, and/or radiation 
therapy. However, there is an urgent need for therapies capable of offering cures to the 
large number of patients with metastatic solid tumors. A few years ago, cancer therapy 
has benefited from several breakthroughs in new alternatives to the typical regimens. 
Immunotherapy has been gaining more and more attention due to its use of specific 
targeting factors to eradicate cancer more efficiently and safely with fewer adverse 
events. Some examples of immunotherapy modalities include monoclonal antibodies 
(mAb) and cancer vaccines. Monoclonal antibodies have been genetically modified in 
order to target specific cancers such as neuroblastomas and other types of brain cancers.17 
Cancer vaccines have also emerged in order to alter the tumor microenvironment in order 
to treat different types of cancers.18 Clinical trials are currently underway in order to test 
these vaccines, although anti-cancer vaccination strategies have largely been ineffective 
to date.19 Another method for cancer management is known as adoptive cell transfer 
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(ACT). This type of therapy makes use of tumor-infiltrating lymphocytes (TIL) that are 
taken directly from the tumor itself and reinfused into the cancer patient. Other therapies 
include T lymphocytes that are virally transduced with a specific, chimeric antigen 
receptor (CAR) also known as CAR-T. This new therapy has shown promising results. 20 
The remainder of this literature review will focus heavily on CAR-T therapy.   
Generation of CAR-T cells   
 The human immune system is composed of a network of two different 
microenvironments of cells; the innate immune system is generally composed of anti-
inflammatory cells that respond quickly to infections in a non-specific pattern while the 
adaptive immune system is composed of cells such as Natural Killer (NK), B, and T cells 
that are more specific to antigens and respond slower then the innate cells. T cells are 
further sub-classified as CD4+ (helper) and CD8+ (killer) T cells. CD8+ T cells are 
heavily implicated in tumor eradication.21 Typically, T cells detect tumors and become 
activated via a two-step process involving the T cell receptor complex (TCR); this is 
outlined in Figure 2.22 
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a      b  
Figure 2: TCR complex and T cell activation. a) The T cell receptor (TCR) consists of an alpha and beta chain. 
This binds to an MHC on an APC and is therefore HLA-dependent.  The signaling,comes from the CD3 
complex. Upon binding with MHC, the immunoreceptor tyrosine-based activation motifs (ITAMS), depicted by 
the rectangles in the CD3 complex, become phosphorylated and lead to T cell activation. b)This model depicts 
the two-step binding process required for T cell activation. The first signal is initiated by the binding of the TCR 
complex to the antigenic peptide (Ag), which is presented by the APC’s MHC.  The second signal is antigen 
independent and is co-delivered by the APC (B7) and leads to activation of T cells when bound to the main co-
stimulatory receptor on T cells (CD28). This second signal increases transcription of IL-2, the stability of its 
mRNA, expression of BCL-X (an anti-apoptotic protein), and lowers the threshold for T-cell activation. 
(adapted from Sadelain et al; Targeting tumors with genetically enhanced T lymphocytes)22 
 
 First, the TCR must bind to the Major Histocompatibility Complex (MHC) on an 
antigen-presenting cell (APC) that displays a fragmented peptide antigen from the 
tumor.23 In order for it to actually become activated and carry out an effective response, 
the T cell must also concurrently receive a co-stimulatory signal from a recruited CD28 
receptor displayed on the T cell surface after binding with the appropriate molecules on 
the APC.21 Without this co-stimulation, lymphocytes are inactivated and either remain in 
that anergic state or they are deleted. The major limitations of this type of recognition and 
activation are MHC-restriction and the need for co-stimulation in order to become 
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affective; tumors are also able to escape immune recognition through the downregulation 
of these MHC molecules rendering them undetectable by T cells.5 
 In 1989, researchers began to focus their attention on overcoming the limitations 
of adaptive immunotherapy by looking at the MHC-restriction of T cells.24 Gross et al. 
was interested in the major differences and similarities between antigen recognition of 
TCRs and that of antibodies. While TCRs recognize antigens via fragments from APCs, 
antibodies are able to bind directly to the antigen itself in its native form with a relatively 
high affinity. The molecular structure of the two entities, however, has been shown to be 
relatively similar. While TCRs have an alpha and beta polypeptide chain spanning the 
membrane, antibodies similarly have a L (light) and H (heavy) region also composed of 
disulfide-linked polypeptides; each of these peptides in TCRs and antibodies has a 
constant (C) and variable (V) region. The binding sites of both molecules are encoded by 
an exon on the V-portion of the gene. Of note, previous data have concluded that the V 
and C regions on TCRs are not only connected to one another spatially such as in 
antibodies but they also have homology to immunoglobulins and thus must be 
structurally similar in formation. Hence, Gross et al. concluded that the TCR V region 
can be manipulated to express a chimeric antibody V region by switching out one for the 
other; this would give T cells higher affinity for the native antigen and eliminate the need 
for MHC-binding as well as dependence on co-stimulatory ligands.  The researchers then 
genetically fused the intracellular C signaling domain of the TCR (CD3ζ) with the V 
region of an antibody domain which was composed of a single chain variable fragment 
(scFv) The resulting transfected, first-generation chimeric T cells exhibited a heightened 
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capability to react to a broad range of antigens without binding to MHC. This was a 
major innovation in immunology because it enabled alteration of the genetic design of 
TCR and thus allowed for the exploitation of T cells in order to target specific tumors, 
given that those tumors can be targeted by a mAb.24 Nevertheless, the genetic fusion of 
scFv with CD3ζ only provided the first signal (the same one as when T cells bind with 
MHC) but not the second signal required (the one from co-stimulatory domains) and thus 
lead to anergy, dysfunctional cytokine release, and eventually apoptosis.25  
Since then, several different generations of CAR-Ts have been developed (Figure 
3)21 with the addition of co-stimulatory domains such as CD28 to enhance T cell 
activation in response to tumor antigen ligation. 
      
 
Figure 3: Generations 1-4 of CAR-T; The structures of the different generations of CAR-T (adapted from Haji-
Fatahaliha et al; CAR-modified T-cell therapy for cancer: an updated review).21  
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 In 2007, Brentjens et al. conducted a study using second generation CAR-Ts that 
targeted NALM-6-expressing tumors in mice which are the model correlates of CD19 B 
cell tumors in humans.26 Like B cell leukemias in humans, these mouse tumors also lack 
the signal for co-stimulatory ligands, minimizing the efficacy of CAR-T. The researchers 
found that the CAR-T were able to completely eliminate systemic tumor cells despite 
lack of co-stimulatory ligands as well as lack of in vivo cytokine secretion. Their findings 
delineated the necessity for in vivo T-cell persistence via multiple infusions in order to 
increase the efficacy of adoptive immunotherapy in systemic tumor eradication.26       
Carpenito et al. attempted to address the limitation of inadequate in vivo 
persistence of previous CAR-T cells by constructing a 3rd generation of CAR-T that 
targeted mesothelin, a common target of carcinomas.27 CD28 and CD137 domains were 
fused attached to the T cells for co-stimulatory support. The results showed higher rates 
of T cell survival, increased cytokine production, and enhanced tumor eradication. The 
efficacy of this study design could have been attributed to a number of reasons. First of 
all, these genetically modified cells were transduced with a lentivirus (as opposed to a 
retrovirus as had been done in previous studies). The researchers thought that the 
lentiviral vectors, since they are more efficiently transduced, lead to shorter in vitro 
culture times and ability to use the CAR-Ts at an earlier time, which correlate to 
decreased telomerase activity and thus allows longer telomere sequences. Longer 
telomere lengths allow for a higher degree of replication. Similarly, previous studies have 
shown that using “younger” lymphocytes correlates with enhanced tumor eradication. 
Secondly, this study suggested that since CD28 increases T cell resistance and in vivo 
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antitumor killing and CD137 is necessary for engraftment, CAR-T efficiency would be 
enhanced with the use of both co-stimulatory domains as opposed to having just one or 
the other. This study depicted even further, the antitumor potential of CAR-T.27           
Eventually the most recent, fourth-generation CAR-Ts were developed that were 
redirected for universal cytokine-mediated killing (TRUCK); in addition to containing 
three co-stimulatory domains, they have the intrinsic ability to release IL-12, a crucial 
cytokine in recruiting inflammatory cells to the tumor site.28 Chmielewski and colleagues 
noted that as cancer progresses, tumor cells have the ability to decrease expression of 
MHC as well as other antigens, thus decreasing detection by cytotoxic T and other 
immune cells. They combined the action of a CAR and multiple co-stimulatory domains, 
with immediate, local release of IL-12 that would recruit macrophages to the tumor site 
in order to enhance tumor cell death. This decreased the effects of systemic IL-12 toxicity 
by locally restricted release of IL-12 only when the T cell was activated. Also, this helped 
to deliver the cytokines directly into the tumor microenvironment in a continuous 
manner, allowing constant cytokine release plus immune cell recruitment and activity 
against the tumor while decreasing the rate of CAR-T apoptosis. In addition, since innate 
immune cells are being recruited to the tumor site, their action of killing is not dependent 
on antigen, so although cancer cells are able to downregulate antigen expression on their 
cell surfaces, the antitumor actions of these inflammatory cells (usually macrophages) 
can still take place.28  
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Clinical Application  
Clinical trials eventually emerged, testing the safety and efficacy of the different 
generations of CAR-T. By 2005, there were only a handful of Phase I clinical trials that 
showed the safety of genetically-modified T cells.29 At that point, it was deemed safe to 
use high amounts of the transfused cells (>109). The patients that were started on CAR-T 
therapy went through a lymphodepleting process before T cell transfer in order to 
eliminate T regulatory cells and other lymphocytes that might compete for cytokines.30 
CAR-T was also given in combination with exogenous IL-2 administration to promote 
persistence of the cells. Nevertheless, there were no tumor responses in these individuals 
with progressive disease before 2005. More clinical trials have emerged since then that 
differed in their targeted antigen, method of transducing the T cells, addition of IL-2 
infusions, dosage, and accompanying conditioning therapy.21   
CAR-T in B-cell malignancies   
To date, immunotherapy has proven to be relatively safe and efficacious in 
treating certain leukemias. One study assessed the clinical activity of CAR-T in patients 
with Chronic Lymphoid Leukemia (CLL).4 A single patient with progressive CLL 
(refractory to Rituximab plus Fludarabine, Rituximab plus Bendamustine, Bendamustine 
alone, and Alemtuzamab) was infused with second-generation autologous CAR-T 
specific for CD-19 B cells. These CAR-Ts were transduced with a lentiviral vector (as 
opposed to the traditional retroviral vector) that coupled a costimulatory receptor 
(CD137) with a signaling domain (CD3-zeta) in order to increase its specificity for the 
CD19 receptor and eliminate dependence on HLA domains. The patient was treated with 
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lymphodepleting chemotherapy four days prior to low-dose CAR-T infusions, which is 
believed to potentiate the ability for CAR-T to kill tumor cells. CAR-T were infused over 
three consecutive days at a total low dose of 1.5x105 cells.4  
Several days later, the patient developed progressively worsening systemic 
symptoms including chills, fevers, fatigue, nausea, and eventually tumor lysis syndrome 
(TLS) on post-infusion day 22 which were reversed with fluids and rasburicase.4 It 
should be noted that the patient did not receive supplemental cytokine administration at 
any point during the clinical trial. Twenty-eight days after the last infusion of CART19 
cells, a bone marrow biopsy, FISH testing, and flow-cytometric analysis revealed absence 
of CLL cells, a negative test for deletion of TP53, and total absence of B cells, 
respectively. Physical exam showed no adenopathy. The same findings were evident 3 
and 6 months post CAR-T infusion and the patient remained in remission at the time of 
the study’s publication, 10 months post-infusion.4  
A second study conducted 2 years later by the same group of researchers 
attempted to use CART therapy in two pediatric patients with relapsing Pre-B cell Acute 
Lymphocytic Leukemia (ALL) refractory to chemotherapy.3 This type of cancer is 
typically extremely aggressive and is accompanied by a poor prognosis. The study design 
was similar to the CLL clinical trial4 in that patients were treated with the same second-
generation CAR019 T-cells over 3 consecutive days, with the exception of differing 
doses.  The first patient’s disease was previously non-responsive to intensive 
chemotherapy consisting of clofarabine, etoposide, and cyclophosphamide. Therefore, it 
was not necessary for her to receive chemotherapy before CAR-T infusion. This patient 
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eventually developed high-grade fevers 4 days after infusions and required 
hospitalization to the ICU, mechanical ventilation and intensive interventions to lower 
her blood pressure. The effects of the cytokine release syndrome were rapidly reversed 
with etanercept and tocilizumab.3  
 The second patient had ALL refractory to umbilical cord-blood transplantation 
and treatment with blinatumomab.3 Her disease was unresponsive to the therapy, so her 
intervention consisted of chemotherapy (etoposide-cyclophosphamide) followed by a 
one-time dose of 107 CTL019 T cells. This patient also developed a fever 6 days post 
infusion, most likely from Cytokine Release Syndrome (CRS) and she was hospitalized.3    
Both patients suffered grade 3-4 adverse events as well as CRS that was reversed with 
Etanercept plus Tocilizumab.3 Both patients had complete remission immediately after 
therapy that was characterized by a decrease in tumors markers detected by flow 
cytometric assays. Most of the circulating lymphocytes in both patients were found to be 
CAR-T; interestingly enough, CAR-T were also found in the CNS of both patients, even 
though no disease was found there before infusion. While one patient’s disease did 
relapse, the second patient was disease free for an ongoing time of 11 months post CAR-
T infusion.3   
CAR-T in solid tumors  
 Adoptive cell therapy (ACT) had emerged as a very promising form of 
immunotherapy for solid tumors such as metastatic melanoma.31 This requires resection 
of tumor nodules in order to collect autologous TILs from the site. After TILs are 
collected, they are expanded in vitro then reinfused back into the patient. Prior to any of 
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this, it is important that the patients undergo lymphodepletion in order to eliminate the 
competition for homeostatic cytokines by T regulatory cells and other lymphocytes.32 
While some studies exhibited a certain degree of objective response, several drawbacks 
exist with this therapy. The TILs were difficult to collect and did not always persist in 
vivo. Also, resection is required where some diseases are too extensive to resect.31      
CAR-T eventually emerged afterwards. The efficacy of CAR-T for solid tumors 
has been shown in preclinical and animal experiments.33 One example is in ovarian 
cancer. A majority of ovarian carcinomas exhibit the mucin biomolecule, more 
specifically MUC-16, on their cell surface.34 Chekmasova et al. conducted an 
experimental design where they transduced human T cells with chimeric antigens specific 
for MUC-CD (an extracellular domain located on MUC-16) in SCID-Beige mice bearing 
the MUC-CD+ tumors. The results exhibited cytolytic activity against ovarian carcinoma 
cells in vitro. Also, when these T cells were infused into the mice, this lead to either 
stable disease or total eradication of disease.34 However, while efficacy has been shown 
in preclinical experiments, so far only the safety of CAR-T has been established in 
clinical trials treating solid tumors; the outcomes and successes are marginal.35 To date, 
CAR-T has been used for a number of solid tumors including sarcomas, CEA+ liver 
metastases, mesothelioma, neuroblastoma, colon cancer, and ovarian cancer.21 
A study by Lamers and colleagues attempted to treat 12 patients with metastatic 
renal cell carcinoma (RCC) that expressed carboxyanhydrase IX (CAIX).35 Patients were 
divided into 3 cohorts and given 8-10 CAR-T infusions varying from 0.2 to 2.1 x 109 
cells. Four patients in the first 2 cohorts experienced grade 2-4 liver toxicities even with 
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the lowest dose of CAR-T; they had to discontinue therapy. The study did not yield any 
clinical responses but it did demonstrate the potency of CAR-T in metastatic RCC even 
in the lowest doses.35 While some of these studies indicate some degree of anti-tumor 
efficacy, such as the study treating neuroblastoma with CAR-T targeting CD171, it is 
minimal and they mostly illustrate overall safety with using CAR-T.33 CAR-T for CEA+ 
liver metastases is discussed in a separate section below.    
Several challenges attribute to the lack of clinical response in solid tumors 
compared to liquid ones. First of all, only a limited number of antigens are specific to 
solid tumors.5 Whereas T cells can be transduced with a number of different vectors for 
leukemias, solid tumors only respond to unique antigens making it more difficult to 
screen for the proper receptors that will target the tumor while sparing healthy tissue. In 
order to do this effectively, researchers claim it is important that CAR-T targets 
neoantigens, which are short peptides created by genetic mutations of malignant cell 
genomes; they are not present in normal tissue.36,37  In addition, co-stimulatory molecules 
pose a challenge for CAR-T in that it still remains unclear which domain is superior in 
increasing CAR-T expansion. While it has been agreed upon that inclusion of a co-
stimulatory domain does in fact influence the therapeutic response, studies are 
inconsistent about whether CD28 is superior to 4-1BB or vice versa.38 Recent studies 
suggest that CD28 accelerates expansion to the point that T cell exhaustion and thus 
decreased persistence occur39 and also that 4-1BB is responsible for the promotion of 
memory T cells while CD28 promotes naïve T cells which are less effective in tumor 
eradication.40 Another study indicates that cytotoxicity in vivo and in vitro were not 
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significantly any different with either domains but CD28 did produce higher amounts of 
cytokines.27 One other issue limiting efficacy in solid tumors is the processing of CAR-
T.5 Migration of CAR-T to tumor sites is dependent on factors such as integrins, 
chemokines, and receptors for these molecules.41 These allow the CAR-T cells to traffic 
and accumulate around the target tumor cells, permitting them to carry out their anti-
tumor functioning, despite the tumor microenvironment. However, altering the genetic 
structure of T cells may in turn decrease expression of these chemokine receptors and 
decrease the ability for CAR-T to find the tumor site.42  
Immunosuppression in the Liver  
 The immunosuppression that takes place in the liver is a specific reason why it is 
difficult to target liver tumors with immunotherapy. The liver plays a major role in any 
individual’s immune system.43 It controls autoimmune responses to various antigens, 
protects against certain pathogens, and is also capable of regulating peripheral tolerance. 
In an attempt to assess how CD4 T cells from the liver function differently than those 
from other organs, Katz et al. removed bulk and CD4 T cells from mouse livers as well as 
from their spleen and compared them in terms of their responses to antigenic stimulation. 
They hypothesized that conventional liver T cell functioning is suppressed by the T cell’s 
native environment. Their findings showed that liver CD4 T cells were different in that 
they produced higher levels of immunosuppressive cytokines. Results also showed that 
when infused with Natural Killer Cells and γδT cells in vitro, conventional T cell 
functioning was suppressed and proliferation was halted in a dose-dependent fashion in 
both the liver and spleen. Other factors may have been responsible for this suppression, 
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however, including cytokines and other cells of the immune system including sinusoidal 
endothelial cells (which can induce anergy) and hepatocytes.43  
 For the most part, when liver T cells are stimulated within their 
microenvironment, this leads to tolerance both within the liver and systemically.44 This 
was portrayed when the delivery of antigens or allografts to the liver failed to induce 
attacks by the immune system. Liver allografts, for example, have been readily accepted 
in numerous cases. Tolerance is thought to be promoted through various mechanisms 
including but not limited to evasion of the immune system, anergy, apoptosis, and the 
promotion of regulatory T cells. Priming of mature T cells in lymphoid tissue as well as 
naïve cells in the liver can also result in tolerance. The sinusoidal architecture of the liver 
plays a role in that it promotes priming of lymphocytes, which eventually leads to 
tolerance. While this may be a positive feature of the liver in terms of therapies for 
autoimmune diseases, it can also be negative in that certain types of immunotherapy, 
including the administration of CAR-T, may impede the liver’s ability to induce an 
immune response, allowing tumors or other diseases such as a viral hepatitis to continue 
growing or to last for longer periods of time.44 Nevertheless, the exact mechanisms and 
consequences of hepatic tolerance must be further investigated in order to create new 
therapies for diseases involving liver.                
CAR-T in CLM  
The immunologic glycoprotein, CEA, is not only expressed by non-cancerous 
epithelial cells of the colonic crypts in the gastrointestinal tract, but it is also over-
produced in several epithelial malignancies, especially colorectal adenocarcinoma, 
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making this tumor marker an attractive target for immunotherapy.45 CAR-T cells that 
readily recognize CEA have been developed by retroviral transduction of the TCR from 
the splenocytes of HLA-A2.1 transgenic mice into human PBLs after substituting a 
single/dual amino acid into the complementarity determining regions (CDR) of the alpha 
and beta domains of the murine TCRs.46,47 This would allow the CAR-T to target cancer 
cells expressing CEA in vitro.  
A study designed by Parkhurst et al. treated 3 patients harboring CEA+ CLM 
refractory to chemotherapy treatment with these autologous CAR-T targeting CEA-
expressing cells in combination with IL-2 administration, post lymphodepleting 
chemotherapy.45 While all 3 patients had significant decreases in CEA levels (a 74-99% 
drop), the levels rose back up again after several months. Two of the patients did have a 
decrease in their metastases (as determined by RECIST criteria), but they eventually 
developed progressive disease by 5-6 months post CAR-T therapy; the third was 
unresponsive to therapy. The fact that normal cells of the GI tract also express CEA, as 
previously mentioned, helps to explain why all 3 of these patients also developed varying 
degrees of transient colitis. Approximately a week after last CAR-T infusion, 
colonoscopies revealed edematous, ulcerated, denuded mucosa and biopsies 
demonstrated acute/chronic inflammation of the atypical epithelium. Budesonide and 
Mesalamine were used to treat two of the patients.45       
Katz et al. conducted a Phase I Hepatic Immunotherapy for Metastases (HITM) 
clinical trial where 6 patients with CEA-expressing liver metastases (secondary to 
primary colorectal adenocarcinoma and pancreatobiliary ampullary carcinoma) were 
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treated with hepatic CAR-T immunotherapy.7 Five out of 6 patients had over 10 liver 
metastases before entrance into the HITM trial; their disease was advanced, non-
resectable, and refractory to several trials of chemotherapy. Upon recruitment, the 
patients were divided into two cohorts; the first cohort received dose-escalation x3 HAI 
CAR-T specifically targeting CEA+ tumors while the second cohort was treated with 
maximum doses (1010 cells) x3 of HAI CAR-T in combination with systemic IL-2 
infusion. Patients were not pre-treated with lymphodepleting chemotherapy. Adverse 
events were limited to grades 1-3 fever, tachycardia, increased liver enzymes, diarrhea, 
and abdominal pain. Results showed an increase in interferon gamma (IFNγ) levels as 
well as a 37% decrease in CEA levels in the second cohort; there were transient, less 
remarkable decreases in cohort 1. Liver biopsies showed necrotic liver metastases in 3 
patients. Death eventually ensued in 5 patients secondary to disease progression and the 
last remaining patient had stable disease even at 38 months follow-up since last CAR-T 
infusion; radiographic tests showed no evidence of disease progression in this patient. 
Overall, this study showed that HAI CAR-T targeting CEA+ tumors is safe in patients 
with advanced metastatic liver disease and has opened the way for further research in 
targeted immunotherapy.7  
 Katz et al. are conducting another study that is currently recruiting patients.48 This 
phase Ib clinical trial, known as the HITM-SIR trial, combines the same regimen of HAI 
CAR-T as previously stated with a one-time intra-hepatic administration of SIR-spheres 
Y-90 microspheres. Selective Internal Radiation Therapy (SIRT) otherwise known as 
Radioembolization is a method of delivering Yttrium-90  (β-emitting isotopes) directly 
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into the microvasculature enclosing non-resectable liver tumors.49 This is done via 
interventional radiology-guided micro-catheter placement into the hepatic artery and 
delivery of these microspheres to pre-specified tumor-burdened areas of the liver. Their 
size (32.5 microns in diameter) allows them to lodge in distal branches (arterioles, 
typically) of the hepatic artery, allowing them to effectively deliver high-energy 
tumoricidal radiation close to targeted areas without affecting surrounding healthy liver 
tissue.49 This type of therapy is typically indicated in patients with liver metastases 
deemed non-resectable and is usually administered as a single dose only with adjuvant 
systemic chemotherapy.50,51  Adverse events include fibrosis, portal hypertension, 
parenchymal volume changes of the liver. 52 By combining this modality, the tumoricidal 
action of CAR-T would be further enhanced.  
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METHODS 
Study design 
The study design will be based on a Katz et al.’s Phase I HITM and currently 
ongoing HITM-SIR clinical trials.7,48 Further information regarding the HITM-SIR trial 
can be found at clinicaltrials.gov. This design will be a Phase II non-randomized, single-
armed, interventional clinical trial using CAR-T therapy targeting CEA+ hepatic, 
unresectable metastases in combination with administration of a one time dose of SIR-
Spheres Y-90 resin microspheres. 63 patients will be recruited to receive 3 intrahepatic 
infusions of the maximum dose (1010) CAR-T every two weeks. The microspheres will 
be administered two weeks following the last CAR-T dose resulting in a 6-week 
treatment course; IL-2 will be given continuously throughout the 6 weeks. Imaging with 
MRI/PET will be done one month before, at 6 weeks, and three months after CAR-T 
therapy. After the three month mark, MRI will be performed every month for a year then 
every 3 months for a year and PET every 6 months for those two years in order to assess 
PFS. Findings from this trial will be compared with the randomized, phase III SIRFLOX 
clinical trial.53 This trial consisted of two treatment arms for patients with metastatic 
CRC; the first was given FOLFOX while the second was given FOLFOX in combination 
with SIRT; median PFS was found to be 10.2 and 10.7 months respectively.53  
 
Study population and sampling 
 Historical control data from the SIRFLOX study53 will be used to compare results 
and to determine sample size. The second cohort group of combination FOLFOX and 
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SIRT had 10.7 months median PFS in a total of 276 participants. For this current trial, a 
sample size of 63 participants with CEA+ liver metastases from a primary colorectal 
adenocarcinoma will need to be recruited (alpha of 0.05,  power of 80%, and standard 
deviation of 2 months)54  in order to detect a 10% increase in PFS months making 
expected median survival of this study 11.7 or close to 12 months.  
 
Recruitment 
Health care providers treating patients with extensive disease will be able to offer 
this therapy for anyone interested that also meets the inclusion criteria. Inclusion and 
exclusion criteria for all participants can be found in Appendix I. Recruitment will take 
place after contact with various hospitals/medical centers and health care providers, 
inquiring about patients that may be eligible. Presentations will also be given at various 
conferences/meetings in order to make providers aware of this trial and as a chance to 
recruit patients. This study will also be uploaded to clincialtrials.gov. If individuals do 
meet appropriate criteria, they will be offered the choice of undergoing treatment. They 
will be contacted via telephone or seen in the clinic by their oncologists who will be well 
informed about this clinical trial. Benefits and drawbacks will be discussed extensively. 
Patients will be able to ask questions and will be told in full detail the implications and 
timeframe of this clinical trial. Written and signed consent for interested participants will 
be gathered before induction into the study.  
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Treatment 
Upon acquisition of consent, eligible subjects meeting the inclusion criteria will 
receive a PET and liver MRI at least a month prior to start of treatment; number and 
diameters of liver metastases will be recorded. In addition, CEA levels will also be 
measured (levels should be >10ng/mL) at the same time. Prior to therapy initiation, 
patients will undergo angiography in order to assess hepatic artery anatomy to ensure that 
it is adequate for arterial infusions. Study subjects then will receive three doses of CAR-T 
cells (1010 cells) with a continuous, systemic IL-2 administration (50,000 U/kg/d) given 
over the course of 6 weeks via an ambulatory infusion pump. CAR-T will be 
administered in two-week increments on days 1, 14, and 28 via percutaneous HAI 
directly into the liver’s circulation. This will be done with 100mL at each administration 
at an injection rate of <2mL/second. At the third and last administration of CAR-T, 
patients will receive a follow-up PET, liver MRI, normal liver core needle biopsy as well 
as tumor core needle biopsy. These tissue samples will be stained with H&E 
(hematoxylin and eosin) and anti-CEA antibody and observed under the microscope for 
evidence of necrosis and fibrosis. Flow cytometry of biopsy tissues will be used to detect 
the presence of CAR-T. These findings will be compared to the findings obtained before 
initiation of therapy. Two weeks following the last CAR-T dose, patients will receive a 
one-time administration of localized SIR-spheres via interventional radiology-guided 
micro-catheter placement into the hepatic artery.49 The procedure will take roughly an 
hour and after getting scanned with CT, to confirm proper placement of the microspheres, 
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patients will be able to return home. Three months later, patient’s serum will be screened 
for presence of anti-CAR antibodies, IFNγ levels, and patients will again receive a follow 
up liver MRI and PET which will be graded by two radiologists in blinded fashion. 
Participants will receive a follow up MRI every month thereafter for the next 12 months, 
given that disease does not progress. Once disease is deemed progressive, imaging will 
cease. If disease is stable, frequency of MRI will drop down to every 3 months for 12 
months after that. PET scans will be performed every 6 months during those 24 months.      
 Patients will be monitored for CRS and assessed for other adverse events using 
the National Cancer Institute’s CTCAE v4.055 as well as the Interim Monitoring Protocol. 
Adverse events are graded on a scale of 1-5 delineating mild, moderate, severe, life-
threatening/disabling, and death-related adverse events respectively. Should patients 
develop severe or life-threatening CRS or other adverse events, treatment with CAR-T 
will be stopped and patients will be treated with the proper protocol for such events.  
CAR-T production in the lab  
This study will utilize leukapheresis at the various medical centers where subjects 
are recruited in order to collect T cells from patients; this will last somewhere from 2-3 
hours. After isolating the peripheral blood mononuclear cells (PBMC), the cells will be 
activated with AIM V media, human AB serum, anti-CD3 mAb, and IL-2 for the next 48-
72 hours. The T cells will then be retrovirally transduced three times in the lab with a 
tandem molecule formed from the fusion of the hMN14 sFv-CD8 hinge region of the 
viral backbone with a hybrid CD28/CD3d fragment; this is to be done in a facility 
capable of processing and manufacturing these CAR-T as well as storing and distributing 
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them back into patients. This process leads to the production of second-generation CAR-
T targeting CEA and it will take roughly 24 hours. The CAR-T will then be washed, 
incubated, and expanded in growth media over a period of 12-17 days before they are 
examined via flow cytometry with specific antibodies for CD3, CD4, CD8. After clinical 
doses of CAR-T are prepared, they will be frozen, stored, and thawed when ready to be 
infused.     
 
Study variables and measures 
The primary endpoint assessed will be PFS in months. After imaging is performed 
via PET and liver MRI, responses will be graded by two radiologists blinded to the trial 
(a third blinded radiologist will be recruited should the original two disagree on a 
particular finding) using mRECIST.56 This criteria focuses on target lesions, which are 
characterized by the largest metastases in diameter that can be found; changes in these 
target lesions are quantified by taking the sum of the diameters of viable tissue and 
averaging them. The average or percent change will depict the tumor response at that 
time; all follow up measurements will be compared to those pre- and immediately post-
therapy. Definitions of tumor responses are summed up in Table 1.56 The same criteria 
exist for Hepatocellular Carcinoma (HCC) as for liver metastases. Progression is defined 
as a ≥ 20% increase in the average of the summed diameters of viable tissue (target 
lesions). The time to progression will be recorded for all study subjects and compared to 
historical data. Secondary outcomes include tumor response rate, extra and intrahepatic 
tumor recurrence rate, adverse events, and overall survival (OS).     
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Table 1: Tumor response definitions for HCC according to mRECIST (adapted from Fournier et al, Imaging 
criteria for assessing tumor response: RECIST, mRECIST, Cheson)56 
 
 
Data collection 
 Data will be collected and recorded at various times throughout the study. Before 
treatment is initiated, CEA levels and number and diameter of metastases will be 
recorded. After treatment, measurement of remaining and/or new tumors will be recorded 
using the mRECIST as well as anti-CAR antibodies, CEA, and IFNγ levels. Data on 
adverse events will also be collected throughout the study using CTCAE v4.0.      
 
Data analysis 
The main purpose of this study is to further analyze the safety and efficacy of 
using CAR-T therapy in combination with radiation therapy in a larger study population. 
Although limited data is available, PFS and other results will be compared with the 
median PFS of the SIRFLOX study (FOLFOX and SIRT arm as control) for liver 
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metastases. Adverse events will be graded. Response rates will be compared with a test of 
proportions. Time to event endpoints will be compared with the log rank test. A trial 
statistician will carry out data analysis.  
 
Timeline and Resources 
 In the summer of 2016, the study proposal will be submitted to the IRB. Upon 
approval, several weeks of design planning will take place. Once patients begin to be 
recruited, the preparation of CAR-T will take roughly 3 weeks and will be performed in 
the laboratory. The duration of this study from start (first PET and MRI) to treatment to 
last follow-up MRI will be around 2 years and 5 months. However, it should be noted 
that it may not be feasible or likely for all the patients to start treatment at the same exact 
time due to lag in recruitment; therefore it can be expected that 3-5 years will be allotted 
for the recruitment, treatment, follow-up, and completion of this study in order to achieve 
the appropriate sample size.  
Resource requirements for study completion include access to: personnel to 
perform leukepheresis; a Good Manufacturing Practice (GMP) Center with the proper 
equipment/supplies (tissue culture flasks, AIM V media, human AB serum, anti-CD3 
mAb, IL-2, retronectin, protamine sulfate, fluorescently labeled antibodies, endotoxin 
assays, machine for flow cytometry, CAR detecting reagents, system to harvest cells, 
freezing media) and protocols to carry out manufacturing and preparation of CAR-T; a 
medical center to carry out angiography, imaging modalities such as PET/MRI/CT, and 
liver biopsies with a pathology center to stain tissues and look at them under a 
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microscope; and lastly, an interventional radiology department for administration of SIR-
Spheres. The study will require a trial manager that will be heavily involved in the trial 
design phase and will be responsible for raising awareness of the clinical trial by giving 
presentations and conducting discussions at various conferences as well as managing trial 
budgets. The rest of the management team will consist of a Principal Investigator, 
statistician, trial programmer, data manager, data clerks, and administrative staff; these 
positions are responsible for various tasks including project management, sampling, data 
collection, data entry, and analysis. Other responsibilities include: CAR-T production in 
the lab, radiologists to image and biopsy patients as well as administer radiation therapy, 
a pathologist to view tissue specimens, and a radiologist familiar with mRECIST to grade 
tumor changes. Regular meetings will be arranged with all team members in order to 
discuss trial initiation, planning, execution, monitoring, and analysis as well as to bring 
up updates or any issues encountered to the entire team. 
 
Institutional Review Board 
 Before initiating any portion of this study, permission must be obtained from the 
IRB before commencing study to approve non-exempt research before beginning trials on 
human subjects. Submission forms and proper documentation will be submitted to the 
Boston University Medical Center Institutional Review Board (BUMC IRB). The BUMC 
IRB will then pre-review the protocol and determine whether it is appropriate to be 
reviewed by the Western IRB, which requires submission of other forms. After approval 
from the WIRB, the trial can then be initiated.  
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CONCLUSION 
Discussion  
 Recent advances have been made in immunology regarding the use of CAR-T 
therapy in liver metastases from colorectal adenocarcinoma. The safety of this therapy 
has thus far, been established. However, studies testing its efficacy are still underway. 
This is the first phase II clinical trial using regionally infused CAR-T in combination with 
SIR-spheres and continuous IL-2 in patients with unresectable, progressive CLM 
secondary to CRC. Hopefully it will demonstrate the efficacy of this treatment regimen in 
either keeping disease stable or lead to tumor regression in these patients, thereby 
prolonging PFS. While general life expectancy among this population is roughly 6-12 
months before recruitment, results may exhibit increased survival, which may thus in 
turn, increase quality of life during this time.    
The process of retrieving T cells from patients is rather safe and can be done in a 
few hours without any major side effects. The processing and transducing of the T cells 
also can be completed in a reasonably short amount of time in the lab; the manufacturing 
method used in this study only takes roughly 3 weeks for T cells to be collected, virally 
transduced, and grown to appropriate, therapeutic numbers before being easily infused 
back into the patient. Also, by injecting the CAR-T directly into the hepatic circulation 
instead of administering them systemically, this would allow a more concentrated 
response against the liver tumor while diminishing systemic adverse events. By adding 
SIR-Spheres to the treatment regimen, this will amplify tumoricidal effects while 
decreasing radiotherapy side effects to healthy tissue. Unfortunately the lab equipment 
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and supplies/treatment needed for this study are expensive, therefore, budgeting will be a 
crucial factor that can not be overlooked.  
 Following up every month with MRI will allow radiologists to pick up the first 
signs of tumor progression as CLM in the liver progresses rather quickly. Since the study 
aims to detect a 10% increase in PFS (in months) compared to the SIRFLOX study, this 
equates to one more month without disease progression; thus checking for this with MRI 
and the mRECIST protocol would allow for that. Also, MRI is relatively safe and there is 
no evidence that it uses ionizing radiation. That being said, participants might consider 
monthly MRIs a hassle. In addition, while it is expected that this treatment regimen will 
increase PFS, it may be that some participants do not react at all and that their metastases 
will neither regress nor become stable by the time treatment is finished.      
Another challenge that might be expected to arise is in acquiring the appropriate 
sample size for this study to be carried out; this may be due to decreased awareness of the 
trial or hesitancy on the part of participants to enter the trial. Also, if the appropriate 
sample size is reached, it may in fact take longer than 5 years to recruit participants.    
Some limitations exist that pertain to solid tumors specifically. While the efficacy 
of CAR-T in solid tumors has been demonstrated in animal models and in the lab, clinical 
trials have not been able to emulate these findings to a significant degree. Reasons for 
this have to do with the proliferation, persistence, and trafficking of CAR-T and these 
factors are heavily affected by the tumor microenvironment and immunosuppression in 
the liver. While the barriers of delivery are being overcome in this study with intrahepatic 
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infusions directly to the liver circulation, persistence of CAR-T has been inconsistent; 
persistence will be measured with fluorescently-labeled antibodies against CAR-T. 
Cytokine signaling has been another issue; T cells need cytokine signaling to 
boost their activity in vivo and to persist. Thus it is reasonable and necessary to give IL-2 
along with CAR-T. However, as it has been evident from the current literature, cytokines 
can cause a number of adverse events. In addition, once the treatment ends and cytokines 
are no longer given, T cells cease to persist at high, efficacious levels. Future trials may 
be designed to avoid this by using 4th generation TRUCK T cells with intrinsic cytokine 
signaling.     
  
Summary 
CLM is a detrimental manifestation of CRC. Once disease progresses to the liver, 
death will almost always ensue, despite multiple rounds of systemic chemotherapy and 
radiation. While resection remains the only curative modality for CLM from CRC, it is 
not always feasible. Immunotherapy has been showing promising results in the treatment 
of CLM. CAR-T has already demonstrated complete remission in several B cell 
malignancies and it has also lead to stable disease in at least one patient with CLM. 
While challenges exist, there are also numerous benefits to using CAR-T therapy for 
cancer treatment including independence from HLA/MHC binding, easy transduction of 
T cells with viral vectors for genetic modification, and ability to use a number of various 
co-stimulator molecules to provide the second signal T cells require for activation. All of 
these characteristics allow greater affinity of CAR-T for tumors, greater specificity for 
 40 
certain tumors by regulating co-stimulatory molecules, and greater prevention for escape 
of tumor cells from immuno-regulation by down regulating surface antigens. All of these 
characteristics are of great importance in solid tumors. 
 
Clinical and/or public health significance 
The cure for cancer is an incredibly important societal goal and even with the 
medical advances that exist today, some cancers are much more difficult to treat than 
others. The aims of this study have been to test the efficacy of using CAR-T 
immunotherapy in combination with localized radiation therapy in the hopes that this 
treatment modality would essentially prolong progression free survival in patients with 
CLM. This would hopefully not only increase quality of life for these patients but would 
give researchers an insight into genetic modification of the immune system to aid future 
studies. Hopefully, further investigation and further clinical trials in immunotherapy will 
soon allow complete remission in not only liquid but also solid tumors as well.   
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APPENDIX 
 
I. Inclusion and Exclusion Criteria for Current Trial 
INCLUSION CRITERIA  
Patient with histologically confirmed diagnosis of CEA+ adenocarcinoma and liver 
metastases. Patient must have either histologic confirmation of the liver metastases or 
histologic documentation of the primary tumor and definitive radiologic evidence of 
liver involvement. Measurable disease is required with lesions of > 1.0 cm by CT. 
Soluble CEA is not acceptable as the sole measure of disease. Limited extrahepatic 
disease is acceptable if confined to the lungs or peritoneal cavity. 
Tumor must be CEA-expressing as demonstrated by elevated serum CEA levels 
(≥10ng/ml) or immunohistochemistry on a biopsy specimen. Archived tissue is 
acceptable for determination of CEA expression. 
Patient must be at least 18 years of age. 
Patient able to understand and sign informed consent. 
Patient with a life expectancy of greater than four months. 
Patient failed at least one line of standard systemic chemotherapy and has unresectable 
disease. 
Patient with adequate organ function 
Acceptable hepatic vascular anatomy as determined by CT, MR, or conventional 
angiography. A nuclear medicine study will be performed to document the absence of a 
significant hepatic-pulmonary shunt (<20%). 
 
EXCLUSION CRITERIA   
Pregnant patients will be excluded from the study. Males who are actively seeking to 
have children will be made aware of the unknown risks of this study protocol on 
human sperm and the need to practice birth control. 
Patients with serious or unstable renal, hepatic, pulmonary, cardiovascular, endocrine, 
rheumatologic, or allergic disease based on history, physical exam and laboratory tests 
will be excluded. 
Patients with active clinical disease caused by CMV, hepatitis B or C, HIV or 
tuberculosis will be excluded from the study. 
Patients who have had cytotoxic and/or radiation therapy within 4 weeks prior to entry 
into the trial or 4 weeks prior to infusion will be excluded. Patients with other 
concurrent malignancies will be excluded. 
Patients requiring systemic steroids will be excluded. 
Patients with unsuitable hepatic vascular anatomy will be excluded from the study. 
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Patients with extrahepatic metastatic disease beyond the lungs or abdominal/ 
retroperitoneal lymph nodes. 
Patients with >50% liver replacement at time of treatment will be excluded. 
Previous external beam radiotherapy to the liver. 
Portal vein thrombosis. 
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